According to GlobalData’s medical device pipeline database, 21 Computed Tomography (CT) Contrast Agents devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 16 are in active development, while the remaining five are in an inactive stage of development. There are 12 products in the early stages of development, and the remaining four are in the late stages of development.

Computed tomography (CT) is a powerful, non-destructive evaluation technique used for producing 2D and 3D cross-sectional image of an object from a flat X-ray image. It is used on patients with a high risk of colon cancer, or full-motion heart scans for patients with high risk of heart disease. It can also be used to image complex fractures, detect infarction, tumors, calcifications, hemorrhage and bone trauma and also acute and chronic changes in the lung parenchyma. This segment includes ionic iodinated CT contrast agents, non-ionic iodinated CT contrast agents and barium CT contrast agents.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Computed Tomography (CT) Contrast Agents pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Computed Tomography (CT) Contrast Agents devices. Overall, most of these Computed Tomography (CT) Contrast Agents pipeline devices are being developed by private entities.

Key players involved in the active development of Computed Tomography (CT) Contrast Agents include Voyageur Pharmaceuticals, Nextrast, Polyaurum, SunTech Medical, University of Chicago, University of Oxford, University of Oxford, University of Texas MD Anderson Cancer Center, Adiposs and Bracco Imaging.

For a complete picture of the developmental pipeline for Computed Tomography (CT) Contrast Agents devices, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.